U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3921
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    47,423.77
    +344.50 (+0.73%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Top Analyst Reports for Mastercard, Eli Lilly & Citigroup

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Sheraz Mian
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Wednesday, December 16, 2020

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Eli Lilly (LLY) and Citigroup (C). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Mastercard shares have outperformed the Zacks Financial Transaction industry in the year to date period (+11.7% vs. +6.3%). The Zacks analyst believes that the company is gaining from solid demand for digital and contactless solutions amid the COVID crisis.

The company executed several acquisitions to supplement organic efforts and diversify revenues over the years, which helped expand its addressable markets and boost core product solutions. It is well poised to gain from consistent cash generating abilities from operations backed by its growing business volumes.

Mastercard’s strong capital position drives investment in business and shareholder value addition. However, steep costs might stress margins. Its cross-border volumes are likely to remain suppressed due to COVID-19 restriction on travel and entertainment. Its third-quarter earnings missed estimates. 

(You can read the full research report on Mastercard here >>>)

Shares of Eli Lilly have gained +33.6% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +2.8%. The Zacks analyst believes that the company’s revenue growth will be driven by higher demand for drugs like Trulicity, Taltz, and others.

Lilly is making significant pipeline progress including its efforts to make therapies to treat COVID-19. It is regularly adding promising new pipeline assets through business development deals.

However, generic competition for several drugs, rising pricing pressure in the United States on key drugs such as Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Citigroup’s shares have gained +12.6% over the past six months against the Zacks Major Regional Banks industry’s rise of +16.4%. The Zacks analyst believes that a diverse business model, focus on core operations and streamlining of international businesses will continue to support Citigroup’s growth.

Citigroup’s streamlining efforts, along with strategic investments in core business, bode well. Also, net interest revenues will likely be supported by loan growth and mix, despite low interest rates environment. Further, shrinking expense base due to the winding-down of legacy assets is aiding the bank’s bottom-line expansion.

Moreover, manageable debt level makes Citigroup less risky in case of any economic downturn. However, pending litigation issues might keep legal expenses elevated for the company. Additionally, a subdued consumer banking business might dent Citigroup's fee income base to some extent.

(You can read the full research report on Citigroup here >>>)

Other noteworthy reports we are featuring today include AstraZeneca (AZN), Advanced Micro Devices (AMD) and Square (SQ).

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Sheraz Mian

Director of Research                                                             

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Revenue Growth, Solid Balance Sheet Aid Mastercard (MA)

Eli Lilly (LLY) Makes Significant Pipeline Progress

Focus on Core Operations Aid Citigroup (C), Legal Woes Linger

Featured Reports

Cancer Drugs Push AstraZeneca's (AZN) Sales, Pipeline Solid

The Zacks analyst says that AstraZeneca's cancer drugs, Lynparza, Tagrisso, and Imfinzi, should keep driving revenues.

AMD Rides on Robust 7 nm Product Portfolio & Partnerships

Per the Zacks analyst, Advanced Micro Devices is benefiting from the strong adoption of the latest 7 nm-based EYPC and Ryzen processors.

Square (SQ) Banks on Solid Cash App Adoption, Bitcoin Growth

Per the Zacks analyst, Square is benefiting from strong Cash App engagement and its growing active customer base.

Delivery Business Aids Uber (UBER) Amid Mobility Weakness

The Zacks analyst is impressed by the growth in Uber's delivery business as order volumes from homebound customers rise.

Moderna's (MRNA) Coronavirus Vaccine Development Encouraging

Per the Zacks analyst, Moderna's foray into the development of an mRNA-based vaccine for coronavirus infection, COVID-19, and rapid progress with it is boosting the company's prospects.

Robust Genetic Health Market Aids Illumina (ILMN)

The Zacks analyst is upbeat about Illumina's efforts to maintain a foothold in the multi-billion gene sequencing worldwide market.

5G Network Technology Drives Ericsson (ERIC) Amid Competition

Per the Zacks analyst, Ericsson should continue to gain from 5G deployments with service providers, particularly in Northeast Asia and North America, driven by investments for technology leadership.

New Upgrades

Solid Demand for Storage Solutions Boost Sunpower (SPWR)

Per the Zacks analyst, with the solar-plus-storage market expanding, SunPower has been increasingly attaching its Helix and Equinox storage systems it's solar systems, thereby boosting revenue growth.

Winnebago (WGO) Bets on Collaborations & Solid Balance Sheet

Winnebago's strategic deal with Newmar Corporation and healthy balance sheet having low leverage and high cash flow are likely to aid the company's bottom line in the future, per the Zacks analyst.

Michaels' (MIK) Strategies Position it for Long-Term Growth

Per the Zacks analyst, Michaels is on track with efforts to boost e-commerce growth through initiatives like BOPUS, as well as the core 'maker' strategy, which bode well for long-term profitability.

New Downgrades

Principal Financial (PFG) Cost & Pension Risk Transfer Ails

Per the Zacks analyst, the company has been witnessing a slowdown in the pension risk transfer pipeline due to lower interest rates.

WEX (WEX) Continues to Grapple With High Debt, Seasonality

The Zacks analyst believes that high debt may limit WEX's future expansion and worsen its risk profile. The company's businesses are affected by seasonal changes.

Foot Locker (FL) Continues to Witness Dismal Gross Margin

Per the Zacks analyst, Foot Locker's gross margin is under pressure due to a lower merchandise margin rate stemming from a higher mix of direct-to-consumer. Elevated freight cost is also a headwind.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Square, Inc. (SQ) : Free Stock Analysis Report
 
Mastercard Incorporated (MA) : Free Stock Analysis Report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
Citigroup Inc. (C) : Free Stock Analysis Report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research